Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Zinger Key PointsCyclacel shares trade on 21.9 million volume vs. 206.9K average, despite no fresh news.Study shows plogosertib may reduce FLC growth while sparing healthy liver cells.Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up OnCyclacel Pharmaceuticals, Inc.CYCCstock is trading higher on Tuesday, with a session volume of 21.9 million compared to the average volume of 206.9K,as per data from Benzinga Pro.Notably, there is no news to justify the stock movement.Trending Investment OpportunitiesAdvertisementArrivedBuy shares of homes and vacation rentals for as little as $100.Get StartedWiserAdvisorGet matched with a trusted, local financial advisor for free.Get StartedPoint.comTap into your home's equity to consolidate debt or fund a renovation.Get StartedRobinhoodMove your 401k to Robinhood and get a 3% match on deposits.Get StartedHere’s what happened with the company recently:Last week, Cyclacel entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad, an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estatedevelopment and construction.The company highlighted a publication from independent investigators published online in the journal Gut.The study’s authors described in the publication reported that DNAJ-PKAc, a fusion oncoprotein known to drive FLC progression, makes the cancer sensitive totreatment with plogosertib.The researchers found that PLK1 is essential for FLC cells, making them highly sensitive to loss of PLK1.A direct interaction was found between DNAJ-PKAc fusions in the centrosome and PLK1, thus promoting mitotic progression.Pharmacologic inhibitors of PLK1, such as plogosertib, significantly reduced FLC growth but spared normal liver cells in patient-derived in vitro and in vivo xenograft models and an orthotopic model.In July, Cyclacel implemented a secondreverse stock split, 1-for-15, and in May, it announced a1-for-16 reverse stock split.In June, Cyclacel announced a private placement yielding gross proceeds of $3.0 million. The company issued series A, B and C warrants to purchase 3.27 million shares for each warrant at an exercise price of 51 cents per share, 60 cents per share and68 cents per share, respectively.CYCCPrice Action:Cyclacel stock is up 318.43% at $13.85 at publication on Tuesday.Loading...Loading...Read Next:Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?Photo: ShutterstockCYCCCyclacel Pharmaceuticals Inc$12.59280.3%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum0.19GrowthN/AQualityN/AValue3.45Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Posted In:BiotechNewsHealth CareTop StoriesMoversTrading IdeasGeneralStories That Matterwhy it's moving